Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics
Evogene Ltd. - Ordinary Shares (EVGN)
Last evogene ltd. - ordinary shares earnings: 2/28 07:00 am
Check Earnings Report
US:NYSE Investor Relations:
evogene.com/investor-relations
Company Research
Source: PR Newswire
Aiming to introduce a new therapeutic strategy for overcoming chemotherapy resistance in lung cancer due to increased expression of cellular pathwaysREHOVOT, Israel, Feb. 17, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries today announced a collaboration with the pioneering research group of Dr. Mark Adams, a leading cancer genomics expert in the School of Biomedical Sciences and Faculty of Health at the Queensland University of Technology (QUT), Australia. This partnership aims to accelerate the discovery and optimization of novel small molecules as potential drug candidates for the treatment of chemotherapy and targeted therapy-resistant non-small cell lung cancer (NSCLC), as well as other cancers.Despite significant advancements in cancer treatment, resistance to standard-of-care chemotherapies and targeted therapies
Show less
Read more
Impact Snapshot
Event Time:
EVGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVGN alerts
High impacting Evogene Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
EVGN
News
- Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory DiseasesPR Newswire
- Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross ProceedsPR Newswire
- Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI™PR Newswire
- Evogene Appoints Prof. John Irwin and Prof. Dan Major to its Scientific Advisory BoardPR Newswire
- Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer GlobeNewswire
EVGN
Sec Filings
- 2/11/26 - Form 6-K
- 2/4/26 - Form 6-K
- 1/15/26 - Form 6-K
- EVGN's page on the SEC website